2014～2024年中成药治疗肺癌的随机对照试验证据图分析OA

Objective:To retrieve and sort out randomized controlled trials(RCTs)of Chinese patent medicines in the treatment of lung cancer from 2014 to 2024 by evidence mapping,so as to understand the evidence distribution and clinical value of relevant studies.Methods:RCTs on Chinese patent medicines for lung cancer published from 2014 to 2024 in CNKI,WanFang,VIP,SinoMed,PubMed,Cochrane Library and EMbase were retrieved.The classification,sample size,intervention measures,course of treatment and efficacy evaluation indexes of Chinese patent medicines were visualized.Quality evaluation was carried out according to the Cochrane risk of bias assessment tool.Results:A total of 596 RCTs were screened out,involving 55 kinds of Chinese patent medicines(18 traditional Chinese medicine injections and 37 oral Chinese patent medicines).Most sample sizes were 61-100 cases,and intervention courses were mainly 6-12 weeks.Chinese patent medicines were mostly used in comprehensive treatment of lung cancer in the forms of concurrent treatment on the basis of combined medication and sequential medication.Outcome indexes were classified and merged according to their functional attributes,involving 11 categories such as short-term efficacy,long-term prognosis and quality of life.Conclusion:Chinese patent medicines have intervention advantages at different stages of lung cancer and are more suitable for the chronic disease management model of lung cancer.However,the overall quality of evidence is low,lacking high-quality RCTs with rigorous design.Insufficient attention has been paid to the diagnostic criteria,objective evaluation of traditional Chinese medicine syndromes and long-term outcomes.Further post-marketing supplementary studies and re-evaluations are still needed.